Last €50.69 EUR
Change Today +0.101 / 0.20%
Volume 2.3K
TEV On Other Exchanges
Symbol
Exchange
New York
OTC US
Mexico
Tel Aviv
Frankfurt
As of 3:18 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEV) Snapshot

Open
€50.75
Previous Close
€50.59
Day High
€50.87
Day Low
€49.00
52 Week High
01/26/15 - €52.80
52 Week Low
02/10/14 - €31.53
Market Cap
43.3B
Average Volume 10 Days
4.3K
EPS TTM
--
Shares Outstanding
855.0M
EX-Date
11/13/14
P/E TM
--
Dividend
€1.15
Dividend Yield
2.02%
Current Stock Chart for TEVA PHARMACEUTICAL-SP ADR (TEV)

teva pharmaceutical-sp adr (TEV) Details

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Its products include Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Provigil and Nuvigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. The company also offers Treanda to treat chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma; Tevagrastim that stimulate the production of white blood cells; Lonquex, which reduces the duration of neutropenia and incidence of febrile neutropenia in adult patients; Eporatio that stimulates the production of red blood cells; and Synribo for chronic myeloid leukemia. In addition, it provides ProAir for the treatment of bronchospasm; QVAR for the treatment of asthma; Qnasl Nasal Aerosol for nasal allergy symptoms in adults; Plan B One-Step and Quartette, which prevents pregnancy; Seasonique and LoSeasonique that are extended-cycle oral contraceptives; Zoely, a regimen combination contraceptive oral pill; and ParaGard, a non-hormonal intrauterine contraceptive. Further, the company offers Enjuvia for vasomotor symptoms associated with menopause; hormone therapy treatments for menopause/perimenopause; therapies for infertility and urinary incontinence; and manufactures active pharmaceutical ingredients. It also distributes third party products. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

44,945 Employees
Last Reported Date: 02/10/14
Founded in 1901

teva pharmaceutical-sp adr (TEV) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical-sp adr (TEV) Key Developments

FDA Approves Teva Pharmaceutical Industries Ltd.'s Version of Astrazeneca Heartburn Drug

Teva Pharmaceutical Industries Ltd. announced that it has received Food and Drug Administration (FDA) approval for the first generic equivalent to Nexium (esomeprazole magnesium) Delayed-Release Capsules in the United States. Nexium is used to treat symptoms of gastroesophageal reflux disease (GERD) and other conditions involving excessive stomach acid such as Zollinger-Ellison syndrome. Teva says that it is preparing to launch the product in the near future.

Teva Pharmaceutical Industries Limited Receives FDA Approval for First Generic Nexium® Delayed-Release Capsules in the United States

Teva Pharmaceutical Industries Ltd. announced the Food and Drug Administration approval of the first generic equivalent to Nexium (esomeprazole magnesium) Delayed-Release Capsules in the United States. Teva is preparing to launch the product in the near future. Nexium Delayed-Release Capsules, marketed by AstraZeneca, had annual sales of approximately $6 billion in the United States as of November 2014.

Mylan Inc. Loses Patent Fight over MS Drug

The Supreme Court ruled against Mylan Inc. and other firms in their challenge of Teva Pharmaceutical Industries' patents for a blockbuster multiple sclerosis drug. The justices ruled 7-2 that a federal appeals court wrongly overturned five of Teva's patents for the drug Copaxone, which generates about $4 billion in annual sales for Teva. The majority told a lower court to reconsider a ruling invalidating the patents. The decision allows the Israel-based company to keep its exclusive rights to Copaxone until September, delaying generic competition from Mylan and the other companies. And it gives Teva more time to shift patients to a longer acting version that won't face competition until 2030. Teva had argued that the U.S. Court of Appeals for the Federal Circuit should not have second-guessed factual findings made by a federal district court that had ruled in Teva's favor. The Supreme Court agreed that the Federal Circuit should have deferred to factual findings made by the lower court. The other companies involved in the case are Momenta Pharmaceuticals Inc. and Sandoz Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEV:GR €50.69 EUR +0.101

TEV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TEV.
View Industry Companies
 

Industry Analysis

TEV

Industry Average

Valuation TEV Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.